ArticleHepatology international2011
Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis.
Article in Hepatology international, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Early intrahepatic recurrence of HBV infection in liver transplant recipients despite antiviral prophylaxis.JHEP reports : innovation in hepatology · 2023Article
- Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B.Microorganisms · 2021Review
- Novel biomarkers for the management of chronic hepatitis B.Clinical and molecular hepatology · 2020Review
- The Role of Hepatitis B Core-Related Antigen.Genes · 2019Review
- The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients.Journal of gastroenterology · 2017Article
- High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation.World journal of gastroenterology · 2016Article
- Prevention and Treatment of Recurrent Hepatitis B after Liver Transplantation.Journal of clinical and translational hepatology · 2016Review
- Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence.International journal of molecular sciences · 2015Review
- Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.World journal of gastroenterology · 2015Article
- Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin.Transplantation · 2015Review
- Enhancement of Programmed Death Ligand 2 on Hepatitis C Virus Infected Hepatocytes by Calcineurin Inhibitors.Transplantation · 2015Article
- Safe and cost-effective control of post-transplantation recurrence of hepatitis B.Hepatology research : the official journal of the Japan Society of Hepatology · 2015Article
- Management of chronic hepatitis B in severe liver disease.World journal of gastroenterology · 2014Article
- Contradictory immune response in post liver transplantation hepatitis B and C.International journal of inflammation · 2014Review
- Hepatitis B immune globulin in liver transplantation prophylaxis: an update.Hepatitis monthly · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe combination of hepatitis B immunoglobulin (HBIg) and nucleos(t)ide analogues has been accepted as the best treatment to control hepatitis B recurrence after orthotopic liver transplantation (OLT). However, the optimal dose of HBIg remains unclear. We have previously reported that high-dose HBIg in the early period followed by low-dose HBIg with nucleos(t)ide analogues offers reliable and cost-effective control of hepatitis B recurrence. The aim of this study was to investigate intrahepatic hepatitis B virus (HBV) reinfection status with our clinically successful protocol.
methodsWe quantified levels of intrahepatic HBV covalently closed circular (ccc) deoxyribonucleic acid (DNA) and serum hepatitis B core-related antigen (HBcrAg), a new serological marker that can estimate intrahepatic cccDNA levels. Nucleos(t)ide analogues were administered in all cases.
resultsNo patients showed recurrence of hepatitis B surface antigen (HBsAg) or HBV-DNA. However, HBV, cccDNA, and HBcrAg were positive in 57% and 48% of patients after OLT, respectively. Pre-OLT serum HBV-DNA and HBcrAg levels correlated linearly with post-OLT cccDNA levels (
conclusionsPatients with high serum HBV-DNA and HBcrAg levels before OLT (particularly >3 log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.